Pfizer's Trumenba just got closer to a new FDA nod. Can it catch up to GlaxoSmithKline's Bexsero?

 Hot on the heels of men B rival GlaxoSmithKline, Pfizer's vaccine Trumenba picked up an FDA “breakthrough” designation that could speed its move toward a bigger market. And with the Pfizer shot's sales lagging behind GSK's Bexsero, Trumenba could use the lift.